Valneva SE (NASDAQ:VALN - Get Free Report)'s share price gapped down prior to trading on Tuesday . The stock had previously closed at $6.41, but opened at $6.22. Valneva shares last traded at $6.23, with a volume of 2,395 shares changing hands.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on VALN shares. HC Wainwright reiterated a "buy" rating and set a $17.00 price target on shares of Valneva in a research report on Tuesday, April 15th. Guggenheim reduced their price objective on Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, May 8th.
View Our Latest Report on VALN
Valneva Stock Up 0.8%
The firm has a market capitalization of $522.73 million, a PE ratio of -48.08 and a beta of 1.85. The firm's 50-day moving average is $6.51 and its 200 day moving average is $5.85. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78.
Valneva (NASDAQ:VALN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.27. The company had revenue of $51.79 million for the quarter, compared to the consensus estimate of $41.80 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. As a group, research analysts forecast that Valneva SE will post 0.13 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Valneva
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its position in Valneva by 14.3% during the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after buying an additional 30,859 shares in the last quarter. ABC Arbitrage SA purchased a new stake in shares of Valneva in the fourth quarter valued at $84,000. Finally, GAMMA Investing LLC acquired a new stake in shares of Valneva during the first quarter valued at $94,000. Hedge funds and other institutional investors own 11.39% of the company's stock.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Featured Stories
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
